Proceedings of ICEGEE 2026 Symposium: AI-Based Medicine and Biological Data Analysis
DOI: 10.54254/2753-8818/2026.AU32497

A Comprehensive Review of Stem Cell Therapy: From Hematopoietic Transplantation to the Horizon of Regenerative Medicine

Shunqiao Liang

HD Shanghai School, Shanghai, China
liangshunqiao2020@163.com

Abstract. Stem cell therapy is a transformative approach in modern medicine, utilizing the unique properties of stem cells—self-renewal and multilineage differentiation—to treat a diverse spectrum of debilitating diseases. This paper, through a literature review method, systematically explores the established clinical applications, recent advances, and future challenges of stem cell therapies. The review focuses on two principal arms: Hematopoietic Stem Cell Transplantation (HSCT), a clinical cornerstone for treating hematological malignancies and blood disorders, and the rapidly expanding field of regenerative medicine utilizing Mesenchymal Stem Cells (MSCs) and Induced Pluripotent Stem Cells (iPSCs). Key findings reveal significant progress in refining HSCT protocols, including reduced-intensity conditioning and enhanced graft-versus-host disease (GVHD) prevention using advanced protocols and cellular agents like MSCs. Furthermore, technological innovations such as CRISPR-based gene editing and engineered cellular therapies, alongside emerging technologies like 3D bioprinting and organoids, are poised to revolutionize the treatment of genetic disorders and solid tumors. The paper concludes that while significant hurdles remain regarding cellular heterogeneity and tumorigenicity, continued research into precision medicine and bioengineering will pave the way for safer, more efficient, and personalized regenerative therapies.

Keywords: Stem Cell Therapy, HSCT, Mesenchymal Stem Cells, Regenerative Medicine

1. Introduction

Stem cells have remarkable ability to self-renew through mitotic division, and are fundamental to the development, growth, maintenance, and repair of the human body's tissues and organs [1]. The clinical application of these cells, collectively known as stem cell therapy, is significant for treating conditions previously deemed incurable, ranging from blood cancers to chronic degenerative diseases [2]. This therapeutic strategy is built on the premise of replacing damaged or diseased cells and leveraging stem cells' powerful immunomodulatory and paracrine functions, which can orchestrate tissue healing and suppress unwanted immune responses [3,4].

The history of stem cell therapy began with the successful establishment of Hematopoietic Stem Cell Transplantation (HSCT) for leukemia and blood disorders, an achievement dating back decades

© 2026 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2026.AU32497

but continually refined to improve patient outcomes [1]. This success has been followed by a rapid expansion into regenerative medicine, driven by the discovery of adult stem cell plasticity and the development of Induced Pluripotent Stem Cells (iPSCs) [4]. Specifically, recent studies highlight improved survival rates and reduced toxicity in HSCT through advanced reduced-intensity conditioning protocols [5], while non-hematopoietic stem cells, particularly Mesenchymal Stem Cells (MSCs), are demonstrating efficacy in treating autoimmune and inflammatory disorders by modulating the immune system [3,5]. According to current literature, both Hematopoietic Stem Cells (HSCs) and MSCs are the most widely studied and clinically applied cell types, with iPSCs quickly following suit [6].

This paper, through a literature review approach, aims to provide a comprehensive overview of stem cell therapy. It details the established principles and modern advances in HSCT, evaluates the emerging therapeutic potential of MSCs and iPSCs in regenerative medicine, and discusses the challenges and future directions, notably concerning gene editing technologies and regulatory frameworks. This research contributes to the existing body of knowledge by synthesizing the clinical transition of these therapies and offering a perspective on their profound significance in shaping the future of personalized and regenerative medicine.

2. The clinical cornerstone: Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic Stem Cells (HSCs) are multipotent cells responsible for generating all mature blood and immune cell lineages, including Red Blood Cells (RBCs), White Blood Cells (WBCs), and platelets [1]. HSCT is a well-established standard of care for various hematological diseases, including leukemia, lymphomas, aplastic anemia, and certain immune deficiency disorders [1]. The core therapeutic mechanism involves eliminating diseased bone marrow cells via high-dose chemotherapy and/or radiation (conditioning) and subsequently restoring healthy hematopoiesis through the infusion of donor or patient-derived HSCs [1]. The success of the transplant is measured by engraftment, the process where infused cells travel to the bone marrow and begin to produce new blood cells, restoring immune function [1].

2.1. Sources and types of HSCT

Hematopoietic stem cells (HSCs) for transplantation are typically harvested from three primary sources, each carrying distinct clinical attributes and recovery profiles [1]. Historically, bone marrow (BM) served as the original source; while its harvest requires an invasive procedure, it yields a rich cellular product, though engraftment is relatively slow, typically taking two to four weeks [1]. In contrast, peripheral blood (PB) stem cells, which are mobilized from the marrow into the bloodstream using growth factors like G-CSF and collected via apheresis, offer the fastest engraftment time of ten to twenty days, thereby facilitating quicker patient discharge and recovery [1]. Finally, umbilical cord blood (CB), collected from the placenta and umbilical cord after birth, has emerged as a newer source often utilized for allogeneic transplants in pediatric patients or those lacking a matched adult donor [1]. Although CB cells are associated with a lower risk of Graft-versus-Host Disease (GVHD), they generally result in longer engraftment times and potentially lower cell doses, challenges that clinicians increasingly overcome through the use of tandem units or ex vivo expansion [1].

There are three main types of hematopoietic stem cell transplantation, categorized by the donor source and their respective clinical implications [1]. In an autologous transplant, the patient's own stem cells are collected and reinfused following high-dose conditioning, a process that eliminates

DOI: 10.54254/2753-8818/2026.AU32497

the risks of immune rejection and Graft-versus-Host Disease (GVHD), though it carries a persistent risk of cancer cell contamination within the graft [1]. Conversely, an allogeneic transplant utilizes stem cells from a compatible related or unrelated donor and is often preferred for aggressive malignancies due to the powerful Graft-versus-Tumor (GVT) effect, where donor T-cells attack residual cancer; however, this approach poses a significant risk of GVHD [1]. Finally, a syngeneic transplant is a specialized option used only when the donor is the patient's identical twin, effectively eliminating the need for complex tissue matching or the long-term use of immunosuppressive drugs [1].

2.2. Modern conditioning and management of complications

Recent advances have focused on making allogeneic HSCT safer and more widely applicable [7]. The development of Reduced-Intensity Conditioning (RIC) was a major breakthrough [1]. RIC uses less intense regimens to suppress the immune system enough to allow engraftment without total marrow obliteration. This significantly reduces regimen-related toxicity and extends the treatment option to elderly patients or patients with pre-existing co-morbidities who could not tolerate traditional myeloablative conditioning [5].

Despite these improvements, the major complications of allogeneic HSCT remain infections (due to prolonged post-transplant immune deficiency) and Graft-versus-Host Disease (GVHD), an immunological disorder where donor T-cells recognize and attack host tissues [1,7].

Modern protocols are specifically engineered to mitigate transplant-related risks through innovative strategies such as haploidentical transplants and advanced immunomodulation. Haploidentical transplants utilize partially matched family donors, which has dramatically increased donor availability and reduced search times [1]. The success of this approach is largely attributed to highly effective Graft-versus-Host Disease (GVHD) prevention protocols, such as the use of post-transplant cyclophosphamide (PTCy) to selectively deplete alloreactive T-cells while sparing regulatory T-cells and stem cells, or through sophisticated ex vivo T-cell depletion techniques [5,7]. Additionally, research into immunomodulation and cellular therapy has demonstrated that Mesenchymal Stem Cells (MSCs) possess potent anti-inflammatory properties; consequently, MSC infusion has been successfully employed either preemptively or as a treatment for steroid-resistant acute and chronic GVHD [8,9]. Furthermore, to address the critical challenge of disease relapse, clinical strategies now involve donor lymphocyte infusions (DLI) and the integration of novel immunotherapies like checkpoint inhibitors to enhance the long-term efficacy of the transplant [7].

3. Advancing regenerative medicine: MSCs and IPSCs

Beyond the hematopoietic system, the therapeutic scope of stem cells has dramatically broadened into regenerative medicine, focusing on repairing and replacing damaged non-hematopoietic tissues. This area is seeing immense growth, particularly with Mesenchymal Stem Cells and Induced Pluripotent Stem Cells.

3.1. MSCs

MSCs are multipotent stromal cells, typically isolated from bone marrow, adipose tissue, or umbilical cord tissue. Their appeal in clinical settings stems from two key biological attributes that make them versatile therapeutic agents [4]:

DOI: 10.54254/2753-8818/2026.AU32497

Immunoprivilege: MSCs are considered "immune privileged" and express low levels of HLA class I and no HLA class II molecules, allowing them to be safely used in an allogeneic (non-matched) setting without causing significant immune rejection. This feature greatly simplifies sourcing and immediate clinical application.

Paracrine and Immunomodulatory Activity: MSCs exert their primary therapeutic effect not merely through differentiation but by secreting a multitude of bioactive factors. These factors include anti-inflammatory cytokines, growth factors, and chemokines that inhibit inflammation, prevent apoptosis, promote local tissue repair, and stimulate angiogenesis (the formation of new blood vessels) [4].

The clinical applications of MSCs are extensive and continue to expand rapidly in clinical trials [4]:

Autoimmune and Inflammatory Diseases: Due to their powerful immunosuppressive capabilities, MSCs are actively used in clinical trials for chronic inflammatory and autoimmune conditions, including Systemic Lupus Erythematosus (SLE), Crohn's disease, and Multiple Sclerosis [4]. They help restore immune balance by regulating the ratio of pro-inflammatory to anti-inflammatory cells.

Tissue Repair and Organ Function: They have shown promise in treating conditions such as Myocardial Ischemia, Acute Myocardial Infarction, and Ischemic Stroke by homing to damaged tissue, reducing fibrotic scar formation, and improving overall organ function [4]. MSCs are also foundational to bioengineering, providing a cellular source for bone, cartilage, and muscle repair, addressing traumatic injuries and degenerative joint diseases. Furthermore, the successful use of MSCs to treat acute steroid-resistant GVHD highlights their potent anti-inflammatory utility across various complex immune scenarios [9].

3.2. Induced Pluripotent Stem Cells (IPSCs)

iPSCs represent a monumental technological leap, pioneered by Shinya Yamanaka, allowing somatic (adult) cells to be reprogrammed back into an embryonic-like, pluripotent state through the ectopic expression of specific transcription factors [10]. This technology successfully navigates both the ethical concerns associated with Embryonic Stem Cells (ESCs) and the limited differentiation capacity of Adult Stem Cells [10].

The primary importance of iPSCs lies in two revolutionary areas: disease modeling and autologous cell replacement. Through disease modeling and drug screening, iPSCs can be differentiated into virtually any cell type—such as patient-specific neurons or cardiomyocytes—for in vitro study, which allows researchers to observe disease development and test drug efficacy within a personalized context. This capability is currently transforming preclinical drug development by offering more accurate human-based disease models compared to traditional methods. Furthermore, in the realm of autologous cell replacement, because iPSCs are derived from the patient's own tissue, the resulting differentiated cells are genetically matched, theoretically eliminating the risk of immune rejection upon transplantation. Clinically, this has already seen success through the differentiation of iPSCs into retinal pigment epithelial cells for transplantation in patients with macular degeneration, marking a world-first in regenerative ocular medicine [9]. Beyond transplantation, advancements are also underway to develop patient-specific gene corrections for genetic disorders like β-Thalassemia by coupling iPSC technology with sophisticated gene editing [5].

DOI: 10.54254/2753-8818/2026.AU32497

4. Future directions and technological horizons

The field of stem cell therapy is currently undergoing rapid evolution driven by technological integration and a deeper understanding of cellular mechanisms. The future direction is defined by three converging avenues: the mastery of cellular engineering, the integration of bioengineering for complex tissue generation, and a focus on precision medicine [1].

4.1. Gene editing and cellular engineering

The synergy between stem cell research and gene editing technologies is revolutionizing the treatment of inherited diseases.

CRISPR/Cas9 and its variants enable precise genome editing, allowing scientists to correct single-gene hereditary diseases, such as Sickle Cell Anemia and β-Thalassemia, directly in patient-derived HSCs ex vivo before reinfusion [3,8]. The emergence of next-generation tools like prime editing and base editing (BE) offers even more accurate modification with reduced risk of off-target effects and DNA double-strand breaks. This level of precision is critical for the safety and efficacy of stem cell-based gene therapy.

Researchers are enhancing stem cell function through genetic engineering, such as overexpressing CXCR4 to boost cell homing ability to ischemic regions (e.g., heart or brain tissue) [5]. Furthermore, the successful field of CAR-T cell therapy is increasingly being integrated with HSCT. For acute myeloid leukemia (AML), HSCT is often required to address severe bone marrow suppression following CAR-T treatments, indicating a developing integration of these powerful cell therapies to optimize cancer eradication and recovery [8].

4.2. Bioengineering, organoids, and 3D bioprinting

A major frontier in regenerative medicine involves engineering complex functional tissues and organs from stem cells, shifting the focus beyond simple single-cell suspensions toward integrated three-dimensional structures. One leading approach is organoid technology, which utilizes stem cells —often iPSCs—to create 3D in vitro micro-tissues that self-organize to mimic the structure and function of specific organs such as the brain, gut, or kidney. These organoids serve as invaluable tools for personalized disease modeling and drug toxicity screening, and they hold significant potential for regenerative transplantation by providing a scalable source of complex human tissue. Complementing this is 3D bioprinting, a technology that employs bio-inks containing stem cells and biomaterials to fabricate structures layer-by-layer with precise spatial control. By aiming to generate functional skin grafts, vascularized bone, or even entire organs for transplantation, 3D bioprinting seeks to address the critical clinical shortage of donors while potentially bypassing the complexities of immune rejection.

4.3. Challenges and regulatory hurdles

Despite the transformative potential of stem cell therapies, several critical challenges must be addressed to ensure their clinical viability and safety. A primary concern, particularly with iPSCs, is the risk of tumorigenicity, where incomplete differentiation or the accumulation of genetic instability during prolonged ex vivo expansion and reprogramming can lead to teratoma formation. Consequently, maintaining the purity and genetic stability of the final cell product is a paramount safety requirement. Furthermore, current research is hindered by cell heterogeneity and a lack of standardization, as variations in cultured stem cell populations affect the reproducibility and

DOI: 10.54254/2753-8818/2026.AU32497

reliability of clinical outcomes. Because methods for cell suspension preparation, dosage calculation, and delivery vary significantly across studies, there remains considerable uncertainty regarding potential side effects and ultimate efficacy. Finally, as these therapies transition toward commercial application, the establishment of rigorous, harmonized regulatory frameworks—such as Good Manufacturing Practice (GMP) for cell manufacturing and banking—is increasingly crucial. These frameworks, alongside stringent ethical oversight, are necessary to address the use of fetal-derived materials and to protect patients from non-evidence-based treatments offered by unregulated clinics.

5. Conclusion

The journey of stem cell therapy, beginning with the successful establishment of HSCT for hematological malignancies, has rapidly expanded into the multifaceted field of regenerative medicine. This study aimed to investigate the current status and future prospects of this field, and the findings indicate that stem cell therapy is poised to become a personalized cornerstone of 21st-century medicine.

The analysis revealed that while HSCT remains a highly effective, curative treatment, modern advancements have made it safer and more accessible through techniques like RIC and haploidentical transplantation. Simultaneously, the emergence of MSCs and iPSCs is driving breakthrough research in non-hematopoietic fields, offering tangible solutions for autoimmune disorders, neurological degeneration, and personalized disease modeling. This research contributes to the existing body of knowledge by highlighting the crucial interdisciplinary progress between clinical medicine and bioengineering technologies, such as CRISPR, organoid technology, and 3D bioprinting, which are making gene-level corrections and complex tissue generation a clinical reality.

This study has several inherent limitations that should be acknowledged. Primarily, as a literature-based synthesis, the conclusions are derived from the analysis of existing publications rather than from original experimental data or primary clinical trials; consequently, the mechanisms and outcomes discussed lack direct empirical validation within this specific work. Furthermore, the scope of the review may be constrained by a selective focus on established clinical milestones, which means that certain emerging studies, niche applications, or negative results in the literature might not have been fully captured, potentially affecting the exhaustive nature of the findings. Future research should therefore aim to bridge these gaps by incorporating primary laboratory data and employing more rigorous systematic review methodologies to provide a more quantitative and comprehensive evidence base. Despite these constraints, this review provides a valuable consolidation of advancements in both HSCT and regenerative medicine, underscoring the necessity for robust clinical and ethical governance in the field.

References

[1] Jose, N. (2017). Stem Cell Therapy. International Journal of Immunological Nursing.
[2] Hussen, B. M. et al. (2024). Revolutionizing medicine: recent developments and future prospects in stem-cell therapy. PMC. (Supplemental Source)
[3] Al-Anazi Khalid Ahmed(2023). Update on the Clinical Applications of Mesenchymal Stem Cells. Journal of Stem Cell Therapy and Transplantation. (Supplemental Source)
[4] Thanaskody, K., et al. (2022). MSCs vs. iPSCs: Potential in therapeutic applications. Frontiers.
[5] Wang, Y., et al. (2025). Exploration and practice: New integration of cellular therapy and hematopoietic stem cell transplantation. Chinese Medical Journal - MedNexus. (Supplemental Source)
[6] Acharya, S., et al. (2025). Stem cell therapies in the clinic. ResearchGate. (Supplemental Source)

DOI: 10.54254/2753-8818/2026.AU32497

[7] Ma, Q., et al. (2024). Navigating stem cell culture: insights, techniques, challenges, and prospects. Frontiers in Cell and Developmental Biology. (Supplemental Source)
[8] Kumar A.&Israr J. (2025). Allogeneic Stem Cell Transplantation: Current Status and Future Directions. Lidsen Publishing. (Supplemental Source)
[9] Guba, M., et al. (2024). Toward better drug development: Three-dimensional bioprinting in toxicological research. (Supplemental Source)
[10] Ogbonna N. (2025). Stem Cell Therapy Success Rates Hit 78%: New Research Reveals Breakthrough Results. GlobalRPH. (Supplemental Source)